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Aim Long-term prognostic impact of coronary artery disease (CAD) severity in stable post-myocardial infarction (MI)
patients is not well known. We examined the impact of CAD severity and co-morbidity on the long-term (1 year
and beyond) risk of cardiovascular events post-MI.
...................................................................................................................................................................................................
Methods
and results
From nationwide administrative and clinical registers, we identified 55 747 MI patients, during 2004–2010, who had
not experienced subsequent MI, stroke, or death within 7 days post-discharge. The risk for primary composite end-
point (MI, stroke, or cardiovascular death) was estimated for the first 365 days after MI (index MI) and from day
366 to study completion (stable post-MI population), corresponding to a mean follow-up of 3.6 (2.2) years. Risk
was assessed using cumulative incidence, multivariable adjusted logistic regression and Cox proportional-hazards
models. The 1-year cumulative incidence for primary endpoint was 20.0% [95% confidence interval (CI), (19.6–
20.3)]. Correspondingly, the 4-year cumulative incidence for primary endpoint was 21.0% (95% CI, 20.6–21.4) in
patients without events on the first year. In multivariable models with no significant stenosis as reference, CAD
severity was the most important risk factor for cardiovascular events the first 365 days [left main stenosis (LMS):
odds ratio and 95% CI, 4.37, 3.69–5.17; 3-vessel disease (VD), 4.18, 3.66–4.77; 2-VD, 3.23, 2.81–3.72; 1-VD, 2.12,–
1.85–2.43] and remained from day 366 to study completion [LMS: hazard ratio and 95% CI, 1.91, 1.64–2.22; 3-VD,
1.85,1.65–2.07; 2-VD, 1.55, 1.38–1.74; 1-VD, 1.30, 1.16–1.45].
...................................................................................................................................................................................................
Conclusion Despite contemporary treatment at baseline, stable post-MI patients’ 4-year outcome was similar to 1-year out-
come after MI, and CAD severity remained a critical risk factor the first year and thereafter.
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Introduction
Improved lifestyle, together with more effective pharmacotherapy
and invasive treatment, has resulted in a decline in first-time coronary
artery disease (CAD) and increased survival in patients with
established CAD.1,2 Despite the decline in mortality from CAD, it
remains one of the leading causes of premature death on a European
scale.2 Aside from an additional risk of premature death, CAD is also
associated with risk of recurrent cardiovascular events, e.g. stroke
and recurrent myocardial infarction (MI), with the highest risk of
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recurrent events during the first year after MI.3–5 This risk is targeted
by a similar guideline recommended treatment duration, but evi-
dence has shown that the risk persists beyond the first year after MI
and that the risk depends on the patient’s risk profile.4–6 With the
projected increase in high-risk patients that stay event-free on the
first year after MI and the associated long-term health-care burden,6
it has become even more relevant to clarify the long-term risk of
recurrent events in stable post-MI patients with distinct risk profiles.
Thus, high-risk patients might benefit from extended tailored treat-
ment approach. However, it is important to highlight the fact that a
considerable proportion of patients with established illness still
appear to receive sub-optimal cardiac care,7 secondary prevention
and cardiac rehabilitation.8 Another serious challenge is that the
prevalence of coexisting chronic illnesses, which in many cases share
the same risk factors as CAD,9 is high and increasing,1 but even more
importantly, are associated with unfavourable prognosis in patients
with CAD.1,10–14 Although CAD severity is one of the strongest risk
factors for long-term outcome,15–20 its importance in late-risk stratifi-
cation and in relation to co-morbidity among stable post-MI patient
who have stayed event-free on the first year is not entirely clear.
Recognizing that CAD extent and severity can been graded differ-
ently from the more simple usage of the number of stenosed
vessels15–17 to the use of more complex scoring system21 and that
the coronary angiography (CAG) lack of ability to detect prognosti-
cally important physiological stenosis,22 we investigated the long-
term (1 year and beyond) impact of CAD severity, using the simple
estimation of CAD severity (no obstructive CAD, 1-, 2-, 3-vessel dis-
ease [VD] or left main stenosis [LMS]), in relation to co-morbidity for
recurrent events in a nationwide study population. Patients conserva-
tively treated who were not receiving CAG, and thus with no infor-
mation on CAD severity, were also included, as conservatively
treated patients fare worse than invasively treated patients and
deserve equal attention in terms of attaining knowledge of risk and
risk factors.
Methods
Data sources
In Denmark, each resident has a unique and permanent identification
number that enables individual-level linkage among several Danish nation-
wide administrative registries, allowing record linkage analysis. (i) The
Civil Registrations System holds information on sex, year of birth, civil sta-
tus and the unique identifier on each Danish resident since 1968.23 (ii)
The Danish National Patient Registry (DNPR) holds information on dates
of admission and discharge, main and secondary discharge diagnoses
according to the International Classification of Diseases, 10th revision
(ICD-10), from 1994, and surgical procedure codes according to the
NOMESCO Classification of Surgical Procedures (NCSP) from 1996.
Since 2002, the DNPR has used the Diagnosis-Related Group system for
hospital reimbursement.24 (iii) The Danish Register of Causes of Death
keeps records on date and cause(s) of death classified according to ICD-
10 since 1994.25 (iv) The Danish Heart Registry (DHR) is a clinical quality
database that keeps track on invasive examinations and treatments, which
include CAG, percutaneous coronary intervention (PCI) and coronary
artery bypass grafting (CABG) since 2000. In addition, risk factors such as
diabetes mellitus (DM) are recorded as well. The DHR has national cov-
erage on CAG since 2006. National coverage is defined as more than
89% of the produces recorded in the DHR as well as in the DNPR in rela-
tion to the number of procedures registered in the DNPR. Each hospital
performing CAG, PCI, or CABG is obligated to report data on performed
procedures to the DHR.26 (v) The Danish National Registry of Medicinal
Product Statistics holds information on date of dispensing, quantity dis-
pensed, strength and formulation of all partially reimbursed prescription
drugs dispensed from Danish pharmacies since 1995. Each drug dispens-
ing is classified according to the International Anatomical Therapeutic
Chemical (ATC) system.27 (vi) The Integrated Database for Labour
Market Research holds information on taxed income gathered by govern-
ment tax authorities.
Study population
We identified all patients >_18 years with first recorded primary or secon-
dary diagnosis of index MI (ICD-10: I21) from 1 January 2004 to 31
December 2010, and who had no prior MI admissions registered in the
previous 12 months (Figure 1). Patients with a recent MI history were not
included, because they probably had a different risk profile per se and
were most likely already in dual treatment and revascularized.
Myocardial infarction population
Patients who survived index MI, without stroke or recurrent MI within 7
days from discharge, were included. The quarantine period from index MI
to 7 days after discharge, at which point all were alive, was chosen to
allow assessment of medication at discharge. Co-morbidities, comprising
prior MI, cerebrovascular disease, peripheral arterial disease, heart failure,
arrhythmia, shock, pulmonary oedema, acute renal failure, chronic renal
failure, DM, cancer, respiratory insufficiency, chronic obstructive pulmo-
nary disease, anaemia, and infection, were defined as the presence of dis-
charge diagnoses up to 10 years prior to the index MI, but prior MI was
identified if any diagnosis since 1994. Identification of important co-
morbidities in an unselected MI population was based on the Ontario
acute MI mortality prediction rules,28 which was modified by expanding
the time window for co-morbidity identification, identifying DM with as
well as without complications and specifying additional co-morbidities of
importance, including for type 2 MI.29,30 The incomplete capture of dis-
charge code-based heart failure and DM was compensated by including
loop diuretics and glucose-lowering drugs. Arrhythmia indicated cardiac
arrest, paroxysmal tachycardia, atrial fibrillation/flutter, and other cardiac
arrhythmias. Shock indicated cardiogenic, hypovolaemic, or other/unspe-
cified shock. Infection indicated urinary tract infection and sepsis of bacte-
rial or fungal origin. Revascularization was measured up to 7 days after
hospital discharge. Concomitant medication was defined as redeemed
prescriptions from 365 days before hospital admission until 7 days after
discharge. Socioeconomic status was measured by means of 5-year aver-
age index income (in quintiles) and civil status (married, living with a part-
ner or living alone).
Stable post-myocardial infarction population
For ‘stable’ post-MI patients, who survived the first 365 days
after the index MI, without a stroke or recurrent MI, identification of co-
morbidities (discharge- as well as drug-based codes) was extended
until 365 days after discharge. Revascularization was measured up to
365 days after hospital discharge. Concomitant medication (excluding
loop diuretics and glucose-lowering drugs) was defined as redeemed
prescriptions from day 244 to day 365 after discharge. Socioeconomic sta-
tus was measured at index MI. A full list of the ICD-10, procedure (NCSP)
and ATC codes used to identify co-morbidity, revascularization and medi-
cation is provided in the Supplementary material online, Table S1.
26 C. €Ozcan et al.
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..Coronary artery disease severity
Identification of CAD severity was based on the findings from CAG and
PCI performed up to 7 and 365 days after hospital discharge for the index
MI and stable post-MI population, respectively. CAD severity was defined
according to the number of obstructive coronary arteries corresponding
to 50% or more narrowing and categorized into 7 groups: no significant
stenosis, 1-, 2-, 3- VD, LMS, missing angiographic data or if no CAG was
performed. LMS with or without additional diseased vessels were catego-
rized as LMS only. For patients with >1 angiography record, the record
with the most severe disease was retained for the analysis. Multi-vessel
CAD (MVD) was defined as 2- or 3-VD or LMS.
Endpoint and follow-up
The primary composite endpoint was defined as the first recorded pri-
mary or supplementary diagnosis of MI (ICD10: I21), ischemic stroke
(ICD10: I63, I64) or fatal cardiovascular disease (CVD) (ICD10: I00-I99).
MI or stroke was considered to be non-fatal regardless of subsequent
death at a later point in time (i.e. >_1 day after non-fatal MI/stroke) and
non-fatal MI or stroke appearing at the same time was classified as non-
fatal MI. For the index MI patients, the length of follow-up was defined as
the time elapsed from day 7 after hospital discharge until the primary
composite endpoint, death, emigration, or end of 1-year follow-up (day
365 after discharge). For the stable post-MI patients, the length of follow-
up was defined as the time elapsed from day 366 after hospital discharge
until the primary composite endpoint, death, emigration, or end of study
follow-up (31 December 2012).
Statistical methods
Continuous and categorical variables were presented as median (inter-
quartile range) and as frequencies (%), respectively. Kruskal–Wallis test
was used for comparison of continuous variables, whereas chi-square test
was used for comparison of categorical variables. Crude incidence rates of
the composite endpoint and its components were calculated per 100
person-years (PY). The overall crude incidence rate of the composite
endpoint was also stratified according to CAD severity, which was a con-
structed ordinal variable: no significant stenosis, 1-, 2-, 3-VD, LMS, missing
data on CAD severity or if no CAG. The 1-year (from day 7 until day 365
after discharge) and beyond (from day 366 until end of study) cumulative
incidence curves for the composite endpoint according to CAD severity
were estimated using the Nelson–Aalen estimator that account for the
competing event of death from non-cardiovascular causes. Logistic regres-
sion and Cox proportional-hazards models were used to estimate the 1-
year and beyond impact of CAD severity and co-morbidity on the compo-
site endpoint, respectively. The models were adjusted for potential con-
founders, which included age, age groups, sex, calendar year,
revascularization status, medication and socioeconomic status (income
and civil status). No significant stenosis, the age group of 50-59 years, high-
est yearly income and married as civil status served as reference groups for
the analyses. Patients with missing data on CAD severity (around 8%)
were excluded in the logistic regression and Cox proportional-hazard
models (complete case analyses). Three sensitivity analyses of the 1-year
and beyond impact of CAD severity and co-morbidity on composite end-
point were conducted with stepwise exclusion of: (i) those with missing
information on CAD; (ii) those with index MI in year 2010 because of dis-
proportionately high occurrence of missing information on CAD severity;
and (iii) those who did not receive CAG. The proportional hazard assump-
tion, linearity of continuous variable, and lack of interaction were found to
be valid unless otherwise indicated. All statistical analyses and data manage-
ment were carried out using SAS, version 9.4 (SAS Institute, Cary, NC,
USA) and R statistic software (version 3.1.1). P-values less than 0.05 were
considered statistically significant.
Ethics
Register-based studies do not require ethical approval according to
Danish legislation. Approval was granted by the Danish Data Protection
Agency (Ref.no. 2007-58-0015/local ref. GEH-2014-014 I-Suite no:
02732).
Figure 1 Selection of study populations.
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Results
Study populations
During the study period, January 2004 to December 2010, 68 096 MI
patients aged 18 years or older were hospitalized, of whom 55 747
(81.9%) patients survived and did not experience a recurrent MI or
stroke 7 days after hospital discharge and were included in the study.
Of the MI population, 43 045 patients (77.2%) survived 365 days
without any subsequent MI or stroke and were classified as the stable
post-MI population with a mean duration of follow-up time of 3.6
years and maximum follow-up time of 9 years (Figure 1 and Table 1).
Irrespective of study population, when stratified according to
CAD severity, age, and co-morbidity burden increased with increas-
ing CAD severity, but at the same time, the proportion of revascular-
ized and treatment with P2Y12 inhibitors declined as opposed to
.................................................................................................
Table 1 Baseline characteristics of the index myocar-
dial infarction population 7 days after hospital discharge
and for the stable post-myocardial infarction population
366 days after discharge
Index MI Stable post-MI
n5 55 747 n5 43 045
Age (IQR), years 70 (20) 68 (20)
Age groups, years
<_49 4992 (9.0) 4033 (9.4)
50–59 8779 (15.7) 7362 (17.1)
60–69 13 277 (23.8) 11 096 (25.8)
70–79 14 153 (25.4) 10 656 (24.8)
>_80 14 546 (26.1) 9898 (23.0)
Male 35 609 (63.9) 28 130 (65.4)
CAD severity
No significant stenosis 4145 (7.4) 4050 (9.4)
1-VD 15 122 (27.1) 14 011 (32.5)
2-VD 7777 (14.0) 6769 (15.7)
3-VD 7020 (12.6) 5566 (12.9)
LMS 1607 (2.9) 1216 (2.8)
Missing data on CAD severity 4223 (7.6) 3.577 (8.3)
No performed CAG 15 853 (28.4) 7856 (18.3)
Co-morbidity
Prior MI 4413 (7.9) 3043 (7.1)
Cerebrovascular disease 5526 (9.9) 3541 (8.2)
Peripheral arterial disease 2239 (4.0) 1739 (4.0)
Heart failurea 19 750 (35.4) 17 035 (39.6)
Arrhythmiab 10 086 (18.1) 8846 (20.6)
Shockc 218 (0.4) 190 (0.4)
Pulmonary oedema 686 (1.2) 526 (1.2)
Acute renal failure 1073 (1.9) 830 (.9)
Chronic renal failure 1330 (2.4) 1040 (2.4)
Diabetes mellitusd 11 290 (20.3) 9048 (21.0)
Cancer 3852 (6.9) 2959 (6.9)
Respiratory insufficiency 1203 (2.2) 980 (2.3)
Chronic obstructive pulmonary
disease
4861 (8.7) 3803 (8.8)
Anaemia 3317 (6.0) 2955 (6.9)
Infectione 1245 (2.2) 1087 (2.5)
Revascularization
PCI 25 425 (45.6) 24 050 (55.9)
CABG 2331 (4.2) 3644 (8.5)
No revascularization 30 322 (54.4) 16 201 (37.6)
Concomitant medicationf
b-Blockers 41 712 (74.8) 30 602 (71.1)
Lipid-lowering treatment 41 971 (75.3) 32 639 (75.8)
Aspirin 46 540 (83.5) 34 235 (79.5)
Nitrate 16 030 (28.8) 7489 (17.4)
P2Y12 inhibitors 34 882 (62.6) 26 144 (60.7)
Clopidogrel 34 802 (62.4) 26 037 (60.5)
Ticagrelor 0 4 (0.1)
Prasugrel 97 (0.2) 106 (0.3)
Glucose-lowering drugs 7528 (13.5) 5901 (13.7)
Loop diuretics 17 373 (31.2) 14 185 (33.0)
Continued
.................................................................................................
Table 1 Continued
Index MI Stable post-MI
n555 747 n543 045
Vitamin-K antagonist/NOAC 4277 (7.7) 2759 (6.4)
Spironolactone 4562 (8.2) 3248 (7.5)
NSAID 16 207 (29.1) 5016 (11.7)
PPI 15 344 (27.5) 9580 (22.3)
Socioeconomic factors
Yearly family income in quintiles
1 10 680 (19.2) 7179 (16.7)
2 10 538 (18.9) 7322 (17.0)
3 10 962 (19.7) 8317 (19.3)
4 11 626 (20.9) 9688 (22.5)
5 (highest) 11 941 (21.4) 10 539 (24.5)
Civil status
Married 29 553 (53.0) 23 968 (55.7)
Living with a partner 3362 (6.0) 2864 (6.7)
Living alone 22 832 (41.0) 16 213 (37.7)
Continuous and categorical variables were expressed as median (IQR) and fre-
quency (%), respectively.
MI, myocardial infarction; IQR, interquartile range; CAD, coronary artery disease;
VD, vessel disease; LMS, left main stenosis; CAG, coronary angiography; PCI, per-
cutaneous coronary intervention; CABG, coronary artery bypass graft; P2Y12,
antiplatelet inhibitors; NOAC, new oral anticoagulants; NSAID, non-steroid anti-
inflammatory drug; PPI, proton pump inhibitor.
aHeart failure was defined as any discharge code indicative of heart failure or use
of loop diuretics.
bArrhythmia was defined as any discharge code indicative of cardiac arrest, par-
oxysmal tachycardia, atrial fibrillation/flutter, and other cardiac arrhythmias.
cShock was defined as any discharge code indicative of cardiogenic, hypovolae-
mic, or other/unspecified shock.
dDiabetes mellitus was defined as any discharge code indicative of diabetes melli-
tus or use of glucose-lowering drugs.
eInfection was defined as any discharge code indicative of urinary tract infection
and sepsis of bacterial or fungal origin.
fRedeemed prescriptions of concomitant medication: from 365 days before until
7 days after discharge for the index MI population, from day 244 to day 365 after
discharge for the post-MI population, except for loop diuretics and glucose-low-
ering drugs, which for the stable group covered the period from 365 before until
365 days after discharge.
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..nitrates. Nevertheless, patients who did not receive CAG were
older, had a greater co-morbidity burden, and received less optimal
medication (Tables 2 and 3, Supplementary material online, Tables S2
and S3).
Furthermore, utilization of CAG, revascularization, and P2Y12
inhibitors increased as opposed to nitrates over the course of time.
Patients enrolled in the early period were older and had more preva-
lent cardiac co-morbidities (MI and heart failure) (see Supplementary
material online, Tables S4 and S5).
Myocardial infarction population
Around 72% of the MI patients underwent CAG of which 41.1% had
MVD. A total of 20 467 primary composite endpoint events (non-
fatal MI, 46.0%; non-fatal stroke, 13.6%; cardiovascular death, 40.5%)
were observed [10.2/100 PYs; 95% confidence interval (CI), 10.1-
10.3], of which 11 129 events (non-fatal MI, 51.9%; non-fatal stroke,
10.0%; cardiovascular death, 38.2%) occurred within the first 365
days (23.8/100 PYs; 95% CI, 23.4–24.3), which corresponded to
20.0% (19.6–20.3), when accounting for the competing risk of non-
cardiovascular death (Table 4 and Supplementary material online,
Table S6). The incidence rate of the primary composite endpoint
increased with increasing CAD severity but was highest in patients
who did not receive CAG. Similarly, the cumulative risk of primary
composite endpoint the first 365 days post-index MI rose from 8.4%
(7.6–9.2) in those with no significant stenosis to 26.4% (24.3–28.6) in
those with LMS (Figure 2A and Table 4). A higher cumulative risk was
noted in patients with unknown CAD severity due to lacking invasive
examination (35.5%, 34.8–36.3). After controlling for confounders,
....................................................................................................................................................................................................................
Table 2 Index myocardial infarction patients’ treatment regimen by coronary artery disease severity
No significant
stenosis
n5 4145
1-VD 2-VD 3-VD LMS Missing data on
CAD severity
n54223
No CAG
n515 853
P-value
n5 15 122 n5 7777 n5 7020 n5 1607
Revascularization
PCI 131 (3.2) 13 094 (86.6) 6110 (78.6) 3407 (48.5) 649 (40.4) 2034 (48.2) 0 (0) <0.001
CABG 16 (0.4) 107 (0.7) 302 (3.9) 1189 (16.9) 393 (24.5) 324 (7.7) 0 (0) <0.001
No revascularization 3998 (96.5) 1969 (13.0) 1434 (18.4) 2574 (36.7) 623 (38.8) 1884 (44.6) 15 853 (100) <0.001
Concomitant medicationa
Nitrate 873 (21.1) 3075 (20.3) 2128 (27.4) 2676 (38.1) 648 (40.3) 1101 (26.1) 5529 (34.9) <0.001
b-Blockers 2717 (65.5) 12 926 (85.5) 6423 (82.6) 5281 (75.2) 1162 (72.3) 3271 (77.5) 9932 (62.7) <0.001
Lipid-lowering treatment 2963 (71.5) 13 761 (91.0) 6910 (88.9) 5743 (81.8) 1254 (78.0) 3552 (84.1) 7788 (49.1) <0.001
Aspirin 3026 (73.0) 13 604 (90.0) 6818 (87.7) 5724 (81.5) 1290 (80.3) 3646 (86.3) 12,32 (78.4) <0.001
P2Y12 inhibitors 1918 (46.3) 12 821 (84.8) 6161 (79.2) 4364 (62.2) 930 (57.9) 2961 (70.1) 5727 (36.1) <0.001
Categorical variables expressed as frequency (%).
VD, vessel disease; LMS, left main stenosis; CAD, coronary artery disease; CAG, coronary angiography; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft; P2Y12, antiplatelet inhibitors.
aRedeemed prescriptions of concomitant medication: from 365 days before until 7 days after discharge. Differences between the groups were found using chi-square test.
....................................................................................................................................................................................................................
Table 3 Stable post-myocardial infarction patients’ treatment regimen by coronary artery disease severity
No significant
stenosis
n5 4050
1-VD 2-VD 3-VD LMS Missing data on
CAD severity
n5 3577
No CAG
n5 7856
P-value
n514 011 n5 6769 n5 5566 n51216
Revascularization
PCI 234 (5.8) 12 532 (89.4) 5715 (84.4) 3102 (55.7) 571 (47.0) 1896 (53.0) 0 (0) <0.001
CABG 27 (0.7) 189 (1.3) 559 (8.3) 1850 (33.2) 534 (43.9) 485 (13.6) 0 (0) <0.001
No revascularization 3790 (93.6) 1387 (9.9) 687 (10.1) 1007 (18.1) 244 (20.1) 1230 (34.4) 7856 (100) <0.001
Concomitant medicationa
Nitrate 560 (13.8) 1786 (12.7) 1118 (16.5) 1242 (22.3) 267 (22.0) 533 (14.9) 1983 (25.2) <0.001
b-Blockers 2288 (56.5) 10 900 (77.8) 5230 (77.3) 4362 (78.4) 923 (75.9) 2641 (73.8) 4258 (54.2) <0.001
Lipid-lowering treatment 2597 (64.1) 11 944 (85.2) 5777 (85.3) 4831 (86.8) 1056 (86.8) 2941 (82.2) 3493 (44.5) <0.001
Aspirin 2702 (66.7) 11 931 (85.2) 5713 (84.4) 4581 (82.3) 1012 (83.2) 2939 (82.2) 5357 (68.2) <0.001
P2Y12 inhibitors 1356 (33.5) 11 057 (78.9) 5202 (76.9) 3540 (63.6) 756 (62.2) 2259 (63.2) 1974 (25.1) <0.001
Categorical variables expressed as frequency (%).
VD, vessel disease; LMS, left main stenosis; CAD, coronary artery disease; CAG, coronary angiography; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft; P2Y12, antiplatelet inhibitors.
aRedeemed prescriptions of concomitant medication from 244 to 365 days after discharge; B, from day 244 to day 365 after discharge. Differences between the groups were
found using chi-square test.
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..CAD severity was the most important risk factor in relation to co-
morbidity (Figure 3A). Other important risk factors were increasing
age, male gender, cerebrovascular disease, peripheral artery disease,
shock, not receiving revascularization, not receiving secondary pre-
ventive medication (b-blockers, statin, aspirin, and P2Y12 inhibitors)
and use of nitrates (Supplementary material online, Figure S1).
Stable post-myocardial infarction
population
Among the almost 82% of the stable post-MI patients that received
CAG, 38.5% had MVD. Until study completion 9338 (non-fatal MI,
38.9%; non-fatal stroke, 17.9%; cardiovascular death, 43.2%) experi-
enced a composite endpoint event (6.1/100 PYs; 95% CI, 5.9–6.2)
(Table 4 and Supplementary material online, Table S6). A similar trend
was noted here. The incidence rate of the primary composite end-
point increased with increasing CAD severity, but was highest in
patients who did not receive CAG. Similarly, the cumulative inci-
dence of the composite endpoints at 4 years follow-up after becom-
ing stable was overall 21.0% (20.6–21.4), but 13.6% (12.5–14.8) in
patients with no significant stenosis and 25.2% (22.5–27.8) in patients
with LMS (Table 4 and Figure 2B). For patients who did not receive
invasive examination, the risk was higher (41.0%, 39.8–42.1). After
adjusting for confounders, CAD severity remained as the most
important risk factor, but its relative importance in relation to co-
morbidity was less pronounced (Figure 3B). Additionally, important
risk factors were increasing age, male gender, cerebrovascular dis-
ease, peripheral artery disease, heart failure, not receiving revasculari-
zation, not receiving statins and use of nitrates (Supplementary
material online, Figure S2).
Sensitivity analysis
To test the robustness of our results, stepwise sensitivity analyses
were carried out for both study populations. Excluding patients with
missing information showed no changes for the risk of events. Data
from the DHR in 2010 showed a higher proportion of missing data
than in the preceding years (see Supplementary material online,
Tables S4 and S5), and by restricting the analysis to the 2004–2009
period no appreciable changes were noted. By further restricting the
analyses to patients with known CAD severity status only, the CAD
severity-stratified estimates remained identical, but the overall esti-
mate reduced from 20.0% (19.6–20.3) to 13.50% (13.1–13.9) in the
index population. Correspondingly, the overall estimate in the stable
post-MI population changed from 21.0% (20.6–21.4) to 16.3% (15.9–
16.8) (data not shown). A similar stepwise approach was carried out
for the multivariable analyses and no appreciable changes were noted
for co-morbidity impact on outcome (see Supplementary material
online, Tables S7 and S8), but for CAD severity, an increase in the
estimates was noted but with overlapping CIs.
Discussion
In this nationwide cohort study, encompassing almost 56 000 MI
patients with a follow-up period of up to 9 years, we examined the
risk of recurrent cardiovascular events (non-fatal MI, non-fatal stroke
or cardiovascular death) in 2 distinct study populations. The key find-
ings were: (i) one in five patients experienced a recurrent cardiovas-
cular event the first 365 days, but for patients surviving the first 365
days without a recurrent cardiovascular event after MI, the risk
remained equally high, with one in five patients experiencing an event
later; (ii) CAD severity remained as the most critical factor for recur-
rent cadiovascular events both before and after the first 365 days; (iii)
co-morbidity was a strong risk factor for cardiovascular events, but
its relative importance was more pronounced in the long term.
The findings from this present study add valuable knowledge to
the limited evidence on impact of CAD severity on recurrent events
in a nationwide post-MI cohort who had been stable for at least 1
year. Using CAD severity, which is a well-established risk factor for
cardiovascular events to identify high-risk patients, we found a dose–
response relationship, but since CAD severity had been modified by
important factors such as revascularization and pharmacotherapy at
baseline, which differed across CAD severity, we did not measure
the true effect of CAD severity. Furthermore, patients with no signifi-
cant stenosis and to a certain extent those conservatively treated
probably had a different underlying cause for MI,22,31 but examining
....................................................................... .........................................................................
....................................................................... .........................................................................
....................................................................................................................................................................................................................
Table 4 Incidence rate (per 100 person-years) and cumulative incidence with 95% confidence interval of the compo-
site endpoint according to time since index myocardial infarction and after becoming stable post-myocardial infarction
Index MI population Stable post-MI population
n5 55 747 n543 045
Incidence rates Cumulative incidence Incidence rates Cumulative incidenceb
Composite endpointa 23.8 (23.4–24.3) 20.0 (19.6–20.3) 6.1 (5.9–6.2) 21.0 (20.6–21.4)
No significant stenosis 9.0 (8.1–10.0) 8.4 (7.6–9.2) 3.8 (3.5–4.1) 13.6 (12.5–14.8)
1-VD 8.7 (8.2–9.1) 8.2 (7.8–8.7) 3.4 (3.2–3.5) 12.6 (12.0–13.2)
2-VD 16.4 (15.5–17.4) 14.5 (13.8–15.3) 4.8 (4.6–5.1) 17.3 (16.3–18.3)
3-VD 29.5 (28.1–30.9) 24.0 (23.0–25.0) 6.8 (6.5–7.2) 24.3 (23.1–25.5)
LMS 33.2 (30.2–36.5) 26.4 (24.3–28.6) 7.5 (6.7–8.4) 25.2 (22.5–27.8)
Missing data on CAD severity 29.4 (26.8–32.3) 15.9 (14.7–17.0) 7.6 (6.8–8.4) 18.5 (16.5–20.5)
No CAG 50.4 (49.1–51.8) 35.5 (34.8–36.3) 13.3 (12.9–13.8) 41.0 (39.8–42.1)
MI, myocardial infarction; VD, vessel disease; LMS, left main stenosis; CAD, coronary artery disease; CAG, coronary angiography.
aNon-fatal MI, non-fatal stroke or cardiovascular death.
bFour years after becoming stable.
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Figure 2 Cumulative incidence of composite endpoint in the index myocardial infarction (A) and stable post myocardial infarction population (B)
according to coronary artery disease severity. A: day 7 after discharge until 1-year follow-up and B: day 366 after discharge until end of follow-up. VD,
vessel disease; CAD, coronary artery disease; CAG, coronary angiography.
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..the extremes of MI patients is valuable, particularly because these
patients are not rare and pose a clinical challenge.
Prevalence of multi-vessel disease
In this present nationwide study on MI with a small percentage of
non-naı¨ve patients, the prevalence of MVD (2-VD or higher) among
CAG recipients was about 41%. This is consistent with a previous
Danish study on first-time MI.32 Another study, with an almost similar
setup to our study, reported a nearly identical prevalence of MVD
(38%) in the index MI,4 and as expected, a lower prevalence of 30%
was reported when only focusing on 3-VD, LMS, and prior CABG.3
The ICD-10 classification system does not account for the different
subtypes of MI. Current evidence suggests that type 1 MI [tradition-
ally corresponding to ST-segment elevation (STEMI) and non-ST-seg-
ment elevation (NSTEMI)] constitutes the largest group.33 In STEMI
and NSTEMI studies, MVD counts for around 50%.34–36 Although
Figure 3 Multivariable analyses showing the impact of CAD severity and co-morbidity on composite endpoint event in the index myocardial
infarction population (A) and stable post-myocardial infarction population (B). The multivariable analysis is based on a complete case approach and
adjusted for age, age-groups, gender, calendar year, revascularization, pharmacotherapy, and socioeconomic status. OR, odds ratio; HR, hazard ratio;
CI, confidence interval; CAD, coronary artery disease; VD, vessel disease; CAG, coronary angiography; LMS, left main stenosis; MI, myocardial infarc-
tion; COPD, chronic obstructive pulmonary disease.
32 C. €Ozcan et al.
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almost 39% had MVD in the stable post-MI population in the present
study, others have reported in the range of 34–58%,37–39 reflecting
important differences in how their stable populations were selected.
Altogether, the prevalence of MVD in MI and stable post-MI is com-
parable with national and international findings, but more impor-
tantly, this shows that a large proportion of MI patients surviving the
first year without events had a high coronary atherosclerotic burden.
Furthermore, we showed in both populations that age and co-
morbidity burden increased with increasing CAD severity, which is in
line with other studies.3,39–41 As expected, we found that MI patients
being event-free on the first year had a more favourable risk profile
(younger, lower proportion of MVD and less degree of prior MI and
stroke), an observation also made by others.5 On that note, a consid-
erable proportion of MI did not receive CAG. These patients were
older and most likely had a higher occurrence of MVD, which in turn
means that the true number of MVD was probably underestimated.
Nevertheless, the complexity of MVD patients underscores the need
for a coordinated effort involving optimal treatment of CAD along
with appropriate management of significant co-morbidities. The
importance of this is emphasized further by the expected increasing
prevalence of CAD combined with the high and increasing burden of
co-morbidity,1 leading ultimately to an increasing economic burden
on the health-care system.
Cardiovascular risk and risk factors
We demonstrated a considerable residual risk for cardiovascular events
during the first year and the first 4 years of follow-up after becoming
stable post-MI. More precisely, one out of 5 MI survivors experienced
an event the first year and the same risk was observed after 4 years in
stable post-MI patients. Studies on long-term prognosis have used dif-
ferent approach to identify high-risk patients.4–6 Similar to the post hoc
study on the PLATelet inhibition and patient Outcomes study (PLATO),3
we focused on CAD severity, which, apart from being the best marker
for coronary atherosclerosis burden, indirectly reflects the co-
morbidity burden. Thus, the study3 found a 1-year risk of 16.3% when
having MVD (defined as 3-VD, LMS or prior CABG), and a study6
restricted to health insurance beneficiaries demonstrated an almost
21% risk after 4 years in high-risk (defined as DM, prior MI or/and
chronic end stage kidney disease) stable post-MI patients. When focus-
ing on overall estimates, a recent nationwide Swedish study5 reported,
similarly to our study, an 18.3% risk on the first year but a higher risk in
the stable post-MI population (20% after 3 years vs. 21% after 4 years).
This latter difference might reflect the fact that we, as opposed to
Jernberg et al.,5 excluded high-risk patients (non-fatal CV events) at
baseline. In a Spanish study, the corresponding estimates after 1 and 4
years were 7.3% and 10.1%, respectively.4 These lower estimates might
be expected in single-centre studies with higher rate of revasculariza-
tion and with a closer clinical follow-up program. Nevertheless, we
showed a relatively high residual risk and that the risk increased with
increasing CAD severity not only during the first year (8.4–26.4%) but
also in the successive years (13.6–25.2%).
More importantly, those treated non-invasively had the highest risk
(35.5% and 41.0%), as reported elsewhere.7,35,42,43 However, after
adjusting for confounders including those related to type 2 MI, MVD
appeared as the most important risk factor for cardiovascular events at
1-year and beyond. This is supported by 1-year- and partially by longer
follow-up studies.3,4,38 Similar to others,4 we showed that the relative
importance of MVD was greater in the first year than in the following
years. At the same time, the importance of co-morbidity in relation to
MVD was more pronounced in the stable post-MI population, which is
in line with other studies.4,38 It is important to bear in mind that some
co-morbidities (e.g., cerebrovascular disease and peripheral artery dis-
ease) share the same risk factor as for CAD, and in general, the extent
of atherosclerosis in the coronary and non-coronary beds is a strong
determinant of long-term prognosis.44 This suggests that the impact of
factors other than MVD becomes more important during long-term fol-
low-up after the CAD has stabilized.
Follow-up and secondary prevention
We showed a slightly lower degree of initiation of secondary preven-
tive drugs (b-blockers, aspirin P2Y12 inhibitors and statins) and utiliza-
tion of invasive strategy in MI as compared to other national
studies.7,32 The most likely reason for this difference lies in the
shorter period for initiating the medication and recording the invasive
procedures. Similar to other studies from abroad, the majority
received evidence-based therapies for CAD at baseline4,5 and
remained on it in the stable post-MI population.5 Although there
have been improvements in initiating secondary preventive drugs, a
large group of MI patients faced undertreatment (primarily in non-
obstructive CAD and conservative strategy) as reported else-
where45; thus, initiating medication at discharge is a critical factor for
medication adherence.46 Performing CAG is another critical factor
that plays a part in the initiation of secondary prevention drugs.7,47,48
A significant proportion of both study populations were assigned a
conservative strategy, a proportion similar to other studies on MI and
stable CAD.32,35,37,42,47,48
With increasing CAD severity, the rate of revascularization
dropped and the prevalence of nitrates increased, and for those
selected for a conservative strategy, a less aggressive treatment was
given. As in previous studies,7,42,43 these patients also appeared to be
older and with greatest co-morbidity burden, crucial factors that are
usually considered in the risk benefit analysis of an invasive strat-
egy.47,48 While some found conservative strategy as being clinically
justifiable,47 others showed that the risk profile has been under-
estimated,49 indicating a risk-treatment mismatch where high-risk
patients have a lower likelihood to receive CAG,40,42 even though
the benefit of an invasive strategy increases with baseline risk.50
In this present study, we showed that the residual risk in stable
post-MI patients with MVD was increased even though we adjusted
for treatment. This indicates that selected patients might benefit from
individualized treatment. That said, we also need to be better to
achieve our treatment goals, as a large share of patients received sub-
optimal secondary prevention drugs (more pronounced in stable
post-MI), invasive strategy (more pronounced in index MI) and
according to the Euroaspire survey III do not enter cardiac rehabilita-
tion programs after discharge.8
Special consideration of myocardial
infarction subgroups
Special attention should be made to patients with no significant
stenosis and conservatively treated patients, as their underlying cause
for MI is different from obstructive CAD.22,31 Both represent the
Coronary artery disease severity and long-term cardiovascular risk in MI patients 33
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opposite ends of the risk spectrum. As outlined above, the high risk
associated with conservative strategy is understandable. Similarly,
although the risk is lower in patients with no significant stenosis com-
pared to those with more extensive CAD, it is still high and might be
linked to undertreatment as well,41 which is in line with our results.
More importantly, for both populations, there is no clear evidence of
appropriate treatment recommendations even though these patients
are not rare in clinical practice.
Limitations
The strength of this study lies in the large nationwide register-based
cohort design, which provided a national study population on MI with
close to complete information on CAD severity (8% missing) among
CAD recipients and long-term follow-up data. A number of limita-
tions inherent to the nature of retrospective studies are present.
First, given that the positive predictive of the diagnosis for MI has
been found high,51 it was not possible to differentiate among STEMI,
NSTEMI, and type 2 MI, which is a subgroup with emerging interest.
Thus, the case mix of MI patients affect the generalizability of the
study results, as STEMI and NSTEMI have different risk/prognosis.
Second, in 2010, the DHR changed its data structure, and therefore,
some variables had missing data, including for the CAD severity for
2010. We believe the information on CAD severity was missing at
random. Another important point is that the DHR has national cov-
erage on CAG only from 2006, which meant that a higher proportion
of CAG without information on CAD (obtained from the DNPR)
was noted in the preceding years. Sensitivity analyses showed no sig-
nificant changes in the main results, other than an almost 7% point
reduction in the overall cumulative incidence noted in both groups
when conservatively treated patients were excluded. Third, some
patients with LMS had evidence of 2- or 3-VD, giving them a more dif-
ferent risk profile. Furthermore, the estimation of CAD severity
relied on the basis of the number of coronary vessels with a stenosis
more than 50%, which is somehow less informative than such as the
Syntax score, which was not registered in the DHR. Fourth, regard-
less of the number of CAG performed during index hospitalization,
patients with different findings on the angiogram were categorized
according to the most severe CAD severity. Fifth, during the study
years, the implementation of high-sensitive assays most likely, to a
certain extent, resulted in reclassification of unstable angina pectoris
to NSTEMI, which meant that certain NSTEMI might have had a
lower risk than NSTEMI in the preceding period. Finally, there is a
lack of information about important clinical parameters such as com-
plete vs. incomplete revascularization, fibrinolytic agents, left ventric-
ular ejection fraction, infarct size, blood pressure, body mass index,
lipid levels, and cardiac rehabilitation programs. Thus, we were
unable to account for achievement of treatment goals, and therefore,
we cannot rule out the effect of unmeasured confounders while esti-
mating the effect of CAD severity and co-morbidity.
Conclusions
This nationwide study showed that stable post-MI patients had
increased risk of cardiovascular events beyond the first year and was
strongly related to CAD severity. Despite medical treatment and
that a large part of patients with multi-vessel disease underwent
revascularization, CAD severity was the strongest risk factor for
recurrent cardiovascular event in a long-term perspective.
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Supplementary material is available at European Heart Journal—
Cardiovascular Pharmacotherapy online.
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